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purpose
Previously published guidelines are available that provide
comprehensive recommendations for detecting and prevent-
ing healthcare-associated infections (HAIs). The intent of this
document is to highlight practical recommendations in a con-
cise format designed to assist acute care hospitals in imple-
menting and prioritizing their Clostridium difficile infection
(CDI) prevention efforts. This document updates “Strategies
to Prevent Clostridium difficile Infections in Acute Care Hos-
pitals,”1 published in 2008. This expert guidance document
is sponsored by the Society for Healthcare Epidemiology of
America (SHEA) and is the product of a collaborative effort
led by SHEA, the Infectious Diseases Society of America
(IDSA), the American Hospital Association (AHA), the As-
sociation for Professionals in Infection Control and Epide-
miology (APIC), and The Joint Commission, with major con-
tributions from representatives of a number of organizations
and societies with content expertise. The list of endorsing and
supporting organizations is presented in the introduction to
the 2014 updates.2
section 1: rationale and statements
of concern
I. Increasing rates of CDI
C. difficile now rivals methicillin-resistant Staphylococcus
aureus (MRSA) as the most common organism to cause
HAIs in the United States.3-5
A. In the United States, the proportion of hospital dis-
charges in which a patient received the International
Classification of Diseases, Ninth Revision, Clinical Mod-
ification discharge diagnosis code for CDI more than
doubled between 2000 and 2009.6 CDI rates may have
leveled off, but they remain at historically high levels.
These increases have been seen in pediatric and adult
populations, but the elderly have been disproportion-
ately affected.6 CDI incidence has also increased in Can-
ada and Europe.7-9 Data on the changing epidemiology
of CDI in pediatric patients are limited and are con-
founded by the prevalence of asymptomatic carriage of
C. difficile among infants and very young children and
by the presence of other pathogens among children with
diarrhea and positive for C. difficile.10-12
B. CDI with onset outside the hospital may be more com-
mon than previously recognized, with more than 50%
of CDIs having onset in the community. In addition,
more than 75% of CDI cases have onset outside the
acute care hospital.13 CDI present on admission to the
hospital may increase the risk of CDI for other hos-
pitalized patients.14-16
C. There have been numerous reports of an increase in CDI
severity.8,9,17-19 Most reports of increases in the incidence
and severity of CDI have been associated with the BI/
NAP1/027 strain of C. difficile.8, 9, 18, 19 Some studies have
found that this strain produces more toxin A and B in
vitro than most other strains of C. difficile, and it may
produce more spores.20-22 It also produces a third toxin
(binary toxin) and is highly resistant to fluoroquinolones.
A strain commonly found in animals, polymerase chain
reaction (PCR) ribotype 078 (which also has tcdC gene
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deletions and carries binary toxin), has been reported to
have a higher 14-day mortality in the United Kingdom
than BI/NAP1/027.23 In the United Kingdom, the BI/
NAP1/027 strain is no longer the predominant strain,
and it occurs less frequently in continental Europe.7 In
the United States, the prevalence of the BI/NAP1/027
strain averages approximately 25%–35% of CDI cases
but ranges from 28% to 85% in adults.24-26
II. Outcomes associated with CDI
CDI is associated with increased length of hospital stay,
costs, morbidity, and mortality in adult and pediatric pa-
tients.27-30
A. CDI increases hospital length of stay by 2.8 to 5.5 days.28
B. Attributable costs of inpatient CDI in 2008 dollars have
been estimated to be $3,006–$15,397 per episode.28 US
hospital costs for CDI management have been estimated
to be $1.0–4.9 billion per year.28 Costs of CDI in the
outpatient and non–acute care settings have not been
assessed.
C. Patients with CDI were almost twice as likely to be
discharged to a long-term care facility than propensity
score–matched controls.27
D. The attributable mortality of CDI is estimated to be
5%–10%,8,9,23,27 leading to an estimated 14,000–20,000
deaths attributable to CDI in the United States each
year.14,29
III. Changing risk factors and possible decrease in CDI treat-
ment response rates
A. For the past 10 years, fluoroquinolones, previously in-
frequently associated with CDI, have been found to be
one of the primary precipitating antimicrobials in re-
cent studies.19,31
1. Virtually every antibiotic has been associated with
CDI. Cephalosporins, ampicillin, and clindamycin re-
main important predisposing antibiotics.15
B. Gastric acid suppression has been recognized as a risk
factor for CDI in some studies.15
1. Some studies suggest that the association between gas-
tric acid suppression and CDI is related to other im-
portant risk factors, such as severity of illness and age.31
2. Gastric acid suppression may be an important risk
factor for CDI outside healthcare facilities.32
C. Several studies suggest that rates of response to treat-
ment of CDI with metronidazole are declining, includ-
ing a randomized, prospective, blinded, severity-strat-
ified study that demonstrated statistically superior rates
of response to vancomycin for severe disease but not




Definitions for CDI surveillance in the United States
and Europe have been published.36,37
A. In the United Kingdom, all cases of CDI in patients
over age 65 years have been required to report to the
HAI surveillance system for National Health Service
acute trusts since January 2004. Reporting for all CDI
cases in those over age 2 years started in April 2007.
B. The Canadian Hospital Epidemiology Committee, a
joint initiative of the Canadian Infectious Diseases So-
ciety and the Canadian Nosocomial Infection Surveil-
lance Program, utilized a standard definition for CDI
surveillance to track nosocomial CDI over a 4-month
period in 1997 and after 2005 in healthcare facilities
across Canada.9 This surveillance now occurs yearly.
C. The Centers for Medicare & Medicaid Services (CMS)
began requiring acute care hospitals participating in
their Inpatient Prospective Payment System to report
laboratory-identified CDI using the National Health-
care Safety Network (NHSN) in January 2013. Public
reports by hospital of CDI rates will occur on the Hos-
pital Compare website beginning in December 2013.
D. Data are lacking to determine the ideal surveillance
definition for healthcare-associated CDI. However,
more important than an ideal definition is the need for
standardization in a CDI surveillance definition. The
following information focuses on the definitions for
CDI surveillance in the United States and Europe.36,37
1. A CDI case is defined as a case of clinically significant
diarrhea or toxic megacolon without other known
etiology that meets one or more of the following cri-
teria: (1) either the stool sample yields a positive result
for a laboratory assay for C. difficile toxin A and/or
B or a toxin-producing C. difficile organism is de-
tected in the stool sample by culture or other means,
(2) pseudomembranous colitis is seen on endoscopic
examination or surgery, and (3) pseudomembranous
colitis is seen on histopathological examination.
a. The definition of clinically significant diarrhea has
not been validated. Criteria used range from 3 or
more than 3 diarrheal bowel movements within 24
hours or less to 6 diarrheal bowel movements in
the previous 36 hours to at least 3 diarrheal bowel
movements per day persisting for at least 2 days.
Recent outbreaks of severe CDI indicate that it is
not always possible to wait 24–48 hours before de-
termining whether a patient has clinically signifi-
cant diarrhea; therefore, diarrhea plus abdominal
cramping has also been used to satisfy criteria for
clinically significant diarrhea.38,39 Conversely, it is
normal for some patients to have 3 or more bowel
movements per day. However, these are usually
formed. Therefore, it is not possible to provide
strict criteria for clinically significant diarrhea that
can be applied to all patients. In general, clinically
significant diarrhea in the context of CDI should
consist of a sustained change in bowel movement
consistency and/or frequency and/or abdominal
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table 1. Clostridium Difficile Infection (CDI) Surveillance Definitions22,23
Case type Definition
Healthcare facility–onset, healthcare facility–associated CDI CDI symptom onset more than 3 days after admission to a healthcare
facility, with day of admission being day 1
Community-onset, healthcare facility–associated CDI CDI symptom onset in the community or less than or equal to 3 days
from admission, provided symptom onset was less than 4 weeks after
the last discharge from a healthcare facility
Community-associated CDI CDI symptom onset in the community or less than or equal to 3 days
after admission to a healthcare facility, provided that symptom onset
was more than 12 weeks after the last discharge from a healthcare
facility
Indeterminate onset CDI CDI case patient who does not fit any of the above criteria for an expo-
sure setting (eg, onset in the community greater than 4 weeks but less
than 12 weeks after the last discharge from a healthcare facility)
Unknown Exposure setting cannot be determined because of lack of available data
Recurrent CDI An episode of CDI that occurs less than or equal to 8 weeks after the
onset of a previous episode, provided that CDI symptoms from the
earlier episode resolved
note. When utilizing laboratory-based reporting symptoms, date and time of stool specimen collection can be used as a surrogate
for symptom onset. If data on the time a patient was admitted (in addition to date) and/or the time stool was collected for testing
are not available, CDI can be considered healthcare facility onset if stool is positive for toxigenic C. difficile or toxin after the third
calendar day from hospital admission, where the first day is the day of admission (ie, a patient admitted on Monday with stool first
positive for C. difficile toxin on Thursday or later is considered to have healthcare facility–onset CDI).
cramping in a patient without other identified
causes.
2. Several CDI definitions have been proposed, includ-
ing community-associated CDI; community-onset
CDI, healthcare facility–associated CDI; healthcare-
onset CDI; and recurrent CDI. Healthcare facilities
should track at least healthcare-onset CDI (Table 1).40
3. Surveillance for CDI is limited by variation in patient
selection for testing, lower sensitivity of toxin enzyme
immunoassays (EIAs), lower specificity of nucleic
acid amplification tests (NAATs), and prolonged
turnaround time for the cell cytotoxicity cell assay as
well as stool culture for toxigenic C. difficile.38,41,42 Lack
of culture-based methods for routine diagnosis also
limits the availability of strains for molecular typing,
although at least one PCR test for C. difficile will
provide a presumptive identification of the BI/NAP1/
027 strain.
II. Identifying patients with CDI
Positive results of diarrheal stool tests for toxigenic C.
difficile or its toxins are the most common methods to
identify patients with CDI.36,37,43
A. Results of positive diarrheal stool tests should be au-
tomatically sent to infection prevention and control
(IPC) professionals and clinicians caring for the patient.
B. Test only patients with clinically significant diarrhea for
C. difficile or its toxins. A positive test for toxigenic C.
difficile and/or its toxins in a patient with clinically sig-
nificant diarrhea is considered diagnostic for CDI. Test-
ing patients without clinically significant diarrhea will
decrease the positive predictive value of a positive test
for CDI.38 Patients with formed stools should not be
tested for C. difficile.44 Automatic, consecutive repeat
testing for C. difficile will also increase the number false
positive tests and has not been associated with better
patient outcomes.45,46 However, if an institution permits
C. difficile testing on nondiarrheal stools, patient record
review is required to ensure that the patient has symp-
toms consistent with CDI.
1. Because of the high prevalence of asymptomatic car-
riage of toxigenic C. difficile among infants and very
young children up to 2 years of age, testing for CDI
is not advised in children under the age of 1 year and
if done should be conducted only in those with di-
arrhea together with testing for alternative causes of
diarrhea, especially rotavirus and norovirus.10,11 Detec-
tion of C. difficile toxin should not be assumed to be
causative of diarrhea in infants and very young chil-
dren unless there are no other plausible explanations.
C. A minority of cases are diagnosed by visualizing pseu-
domembranes at endoscopy and/or by histopathology
without stool testing.43
III. Methods used for CDI surveillance
A. Conducting CDI surveillance to determine CDI rates
provides a measure to determine the burden of CDI at
a healthcare facility. These data are also utilized to assess
efficacy of interventions to prevent CDI. When reported
back to healthcare providers and hospital administra-
tors, CDI rates can be applied as a tool to improve
adherence to CDI preventive measures.
1. When conducting CDI surveillance, healthcare facili-
ties can use traditional infection surveillance reporting
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or use laboratory-based reporting. Traditional report-
ing involves chart review to determine the date of
symptom onset and whether the patient meets the sur-
veillance definition for CDI. Potential cases are typi-
cally identified by a laboratory test on stool positive
for C. difficile and/or its toxins. Laboratory-based re-
porting also utilizes positive tests to identify cases, but
chart review is not performed. Rather, it is assumed
that all positive tests are patients with CDI, and the
date of stool collection is used as a proxy for the date
of symptom onset. Comparisons between the methods
of surveillance have been performed, and the 2 meth-
ods typically have good concordance in correctly
categorizing CDI cases into the proper surveillance def-
inition.47,48 Although there are concerns that labora-
tory-based surveillance is less accurate and more likely
to incorrectly classify community-onset CDI cases as
hospital onset, this is not always the case.47 Even with
the potential for some misclassification, the time sav-
ings of laboratory-based surveillance are often deter-
mined to outweigh the risks.47,48
B. Surveillance can be performed in specific wards or units
and/or an entire healthcare facility level.
C. Laboratories performing C. difficile testing should re-
port results to IPC professionals daily. The CDI rate
can be expressed as the number of CDI case patients
per 10,000 patient-days.
1. Calculation of this rate is as follows: (number of case
patients/number of inpatient days per reporting pe-
riod) # 10,000 p rate per 10,000 inpatient-days.
2. To convert the rate per 10,000 patient-days to the rate
per 1,000 patient-days, divide the rate by 10 (con-
versely, to convert a rate from 1,000 patient-days to
10,000 patient-days, multiply the rate by 10).
D. Because of a lack of published data on CDI surveillance
utilizing similar case-finding methods and surveillance
definitions, specific definitions for what constitutes an
“outbreak” or “hyperendemic” rate cannot be provided
at this time.
1. An outbreak can be defined as an increase in CDI in
time and/or space believed to be greater than that
expected by chance alone.
2. A hyperendemic rate can be defined as a persistently
elevated CDI rate compared with past rates or com-
pared with other similar healthcare facilities.
E. To adjust for factors outside a healthcare facility’s con-
trol with regard to CDI rates, a risk stratification model
has been proposed for use in NHSN and will be uti-
lized for future public reporting of US hospital-onset
CDI rates (http://www.cdc.gov/nhsn/PDFs/mrsa-cdi
/RiskAdjustment-MRSA-CDI.pdf). The factors by
which hospital rates are adjusted include the type of
laboratory test in use, the prevalence of CDI on ad-
mission, bed size, and medical school affiliation. The
risk-adjusted metric that will be publicly reported is the
standardized infection ratio defined as the number of
observed CDI cases divided by the expected number
based on hospital risk stratification.
section 3: background—strategies
to prevent cdi
I. Summary of existing guidelines and recommendations
A. Published guidelines on the management of CDI are
few, and only some address CDI prevention.44,49-51
1. Most data published on CDI prevention are from
single-center before-after studies conducted in re-
sponse to outbreaks or elevated CDI rates. Often sev-
eral concomitant interventions are performed, mak-
ing it difficult to determine the relative importance
of one intervention relative to another. Before-after
studies are also limited by time-related biases that are
difficult to adjust for in the absence of a control group
or properly conducted analyses, such as interrupted
time-series analysis.52,53 However, several studies have
utilized these techniques, demonstrating the impor-
tance of antimicrobial stewardship and its role in pre-
venting CDI.54-57
B. C. difficile shares many common epidemiologic charac-
teristics with other antimicrobial-resistant gram-positive
organisms, such as MRSA and vancomycin-resistant en-
terococci (VRE). Both the skin and the environment of
colonized patients becomes contaminated, and health-
care provider hands may become contaminated by
touching the environment or the patient.58-61 The major
difference among these 3 organisms is that C. difficile
forms spores, whereas the other 2 do not. The formation
of spores poses unique challenges for hand hygiene and
environmental disinfection practices, since C. difficile
spores are resistant to the bactericidal effects of alcohol
and the most commonly used hospital disinfectants. Al-
though alcohol-based hand hygiene products are inef-
fective at removing or disinfecting C. difficile spores in
controlled laboratory experiments, no clinical study has
demonstrated an increase in CDI with the use of these
products or a decrease in CDI with soap and water.62-68
Conversely, several of the studies did identify decreases
in MRSA63-65,68 or VRE64 associated with the use of
alcohol-based hand hygiene products.
A recent intensive care unit–based study found ad-
mission to a room of a patient with CDI to be a risk
factor for CDI, but 90% of patients who developed CDI
did not have this risk factor.69 Other studies that have
examined sharing a room with a patient diagnosed with
CDI or being admitted to a room after a patient with
CDI was discharged from that room have not found these
exposures to be risk factors for CDI.59,70-72 In addition,
use of sporicidal methods to clean the environment out-
side of outbreak settings has not consistently demon-
strated a reduction in CDI with these methods.73-75 These
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data indicate that although the environment can be an
important source of C. difficile, indirect transmission by
healthcare professionals may be the major route by which
patients acquire C. difficile.
C. General strategies to prevent CDI per previously pub-
lished guidelines44,49,51,76 include the following:
1. Methods to reduce the risk of CDI if the organism
is encountered by the patient.
a. Antimicrobial usage restriction and stewardship.
2. Methods to prevent the patient from exposure to C.
difficile (disinfection and barrier methods).
a. Avoid use of electronic thermometers; the handles
become contaminated with C. difficile.
b. Use dedicated patient care items and equipment.
If items must be shared, clean and disinfect the
equipment between patients.
c. Use full-barrier precautions (gowns and gloves) for
contact with CDI patients and for contact with
their body substances and environment (contact
precautions).
d. Place patients with CDI in private rooms if avail-
able. Give isolation preference to patients with fecal
incontinence if room availability is limited.
e. Perform meticulous hand hygiene on the basis of
Centers for Disease Control and Prevention (CDC)
or World Health Organization (WHO) guidelines
before and after entering the room (ie, to coincide
with before patient contact and after removing
gloves) of a patient with CDI with soap and water
or an alcohol-based hand hygiene product (routine
or endemic settings). Perform hand hygiene with
soap and water preferentially instead of alcohol-
based hand hygiene products after caring for a pa-
tient with CDI in outbreak or hyperendemic set-
tings. Ensure that proper hand hygiene techniques
are used when hand washing with soap and water
is employed.77
f. Perform environmental decontamination of rooms
of patients with CDI using sodium hypochlorite
(household bleach) diluted 1 : 10 with water or an
Environmental Protection Agency (EPA)–approved
sporicidal product in an outbreak or hyperendemic
setting.
g. Educate healthcare personnel (HCP) and hospital
administration on clinical features, transmission,
and epidemiology of CDI.
D. Other important principles to be aware of when caring
for patients with CDI.
1. Perform testing for C. difficile only on unformed di-
arrheal stools from patients with clinically significant
diarrhea (toxin testing of formed stool is strongly
discouraged).
2. Do not place patients at high risk for CDI on pro-
phylactic antimicrobial CDI therapy (eg, metroni-
dazole or vancomycin).
3. Do not treat or decolonize asymptomatic C. difficile
carriers. Antimicrobial therapy is not effective for
decolonization.
4. Do not conduct repeat testing for C. difficile if a pa-
tient has had a positive stool for C. difficile unless
symptoms resolved with treatment and then returned
after treatment discontinuation (ie, do not perform
test of cure in successfully treated CDI patients).
5. Most patients who are clinically cured with treatment
will continue to have toxigenic C. difficile in their stool
for multiple weeks. This is not an indication of treat-
ment failure. Therefore, test of cure should not be
conducted if a patient is being transferred to another
healthcare facility. It is not appropriate for the ac-
cepting facility to refuse the patient until “clearance”
has been documented with unnecessary stool testing.
II. Infrastructure requirements
A. Trained IPC personnel.
1. IPC personnel must have knowledge about risk fac-
tors and methods to prevent CDI. They must also be
trained in how to determine when a case of CDI is
healthcare associated and how to calculate CDI rates.
B. Method to identify CDI patients.
1. IPC personnel must be able to identify CDI patients
as soon as possible after they are diagnosed. This is
necessary to ensure that patients are placed under
contact precautions in a timely fashion. These data
can also be used to calculate CDI rates.
C. Ability to place patients with CDI under contact
precautions.
1. Contact precautions require the ability to place pa-
tients in a private room (preferably) or to cohort
patients with CDI as well as to place materials nec-
essary for compliance with contact precautions (eg,
gowns and gloves) in an easily accessible space outside
the patient room.
2. Place a sign indicating that the patient is under con-
tact precautions outside the patient’s room. The sign
should be in English and Spanish (or other language)
if Spanish (or other language) is a commonly spoken
language in the community or among healthcare
providers.
3. If there are a limited number of single-bed rooms,
patients with stool incontinence should preferentially
be placed in private rooms.
4. If it is necessary to cohort patients, cohort patients
colonized or infected with the same organism(s) (eg,
do not cohort patients with CDI who are discordant
on VRE or MRSA colonization status).
5. Dedicated equipment should be readily available for
healthcare providers (eg, stethoscopes). If dedicated
equipment is not available, responsibility for who will
clean and disinfect equipment, when it will be cleaned
and disinfected, and how it will be cleaned and dis-
infected must be clearly stated.
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table 2. Grading of the Quality of Evidence
Grade Definition
I. High Highly confident that the true effect lies close to that of the estimated size and direction of the
effect. Evidence is rated as high quality when there is a wide range of studies with no major
limitations, there is little variation between studies, and the summary estimate has a narrow
confidence interval.
II. Moderate The true effect is likely to be close to the estimated size and direction of the effect, but there is
a possibility that it is substantially different. Evidence is rated as moderate quality when there
are only a few studies and some have limitations but not major flaws, there is some variation
between studies, or the confidence interval of the summary estimate is wide.
III. Low The true effect may be substantially different from the estimated size and direction of the effect.
Evidence is rated as low quality when supporting studies have major flaws, there is important
variation between studies, the confidence interval of the summary estimate is very wide, or
there are no rigorous studies, only expert consensus.
note. Based on Grades of Recommendation, Assessment, Development, and Evaluation (GRADE)122 and the
Canadian Task Force on Preventive Health Care.123
6. Have systems in place to facilitate communication
among IPC, admitting, nursing, and environmental
service departments and develop contingency plans
for limited bed availability conditions.
D. Provide educational materials for patients, family mem-
bers, and HCP that include explanations of CDI, why
contact precautions are necessary, and the importance
of hand hygiene.
E. Provide adequate resources and training for environ-
mental service personnel to ensure proper cleaning of
rooms.
section 4: recommended strategies
for cdi prevention
Recommendations are categorized as either (1) basic practices
that should be adopted by all acute care hospitals or (2)
special approaches that can be considered for use in locations
and/or populations within hospitals when HAIs are not con-
trolled by use of basic practices. Basic practices include rec-
ommendations where the potential to impact HAI risk clearly
outweighs the potential for undesirable effects. Special ap-
proaches include recommendations where the intervention is
likely to reduce HAI risk but where there is concern about
the risks for undesirable outcomes, where the quality of evi-
dence is low, or where evidence supports the impact of the
intervention in select settings (eg, during outbreaks) or for
select patient populations. Hospitals can prioritize their ef-
forts by initially focusing on implementing the prevention
approaches listed as basic practices. If HAI surveillance or
other risk assessments suggest that there are ongoing oppor-
tunities for improvement, hospitals should then consider
adopting some or all of the prevention approaches listed as
special approaches. These can be implemented in specific
locations or patient populations or can be implemented hos-
pital-wide, depending on outcome data, risk assessment, and/
or local requirements. Each infection prevention recommen-
dation is given a quality-of-evidence grade (Table 2).
I. Basic practices for prevention and monitoring of CDI: rec-
ommended for all acute care hospitals
1. Encourage appropriate use of antimicrobials (quality of
evidence: II).
a. Non-CDI treatment antimicrobials. Although the qual-
ity of evidence to recommend “encourage appropriate
use of antimicrobials” to prevent CDI does not meet
level 1 criteria (Table 2), the CDI panel felt that ap-
propriate antimicrobial use as a CDI prevention mea-
sure is essential to any CDI prevention program. A
major risk factor for hospitalized patients to acquire
C. difficile is antecedent antimicrobial exposure.71,78
Encouraging appropriate antimicrobial use has been
associated with reductions in CDI incidence in both
endemic and outbreak settings.54-57 Appropriate an-
timicrobial use includes both avoiding antimicrobial
exposures if the patient does not have a condition for
which antimicrobials are indicated (eg, asymptomatic
bacteriuria in a nonpregnant patient) and selecting
antimicrobials associated with a lower risk of CDI
when possible.79
b. CDI treatment antimicrobials. Assuring that patients
with CDI are receiving appropriate severity-based
treatment for their infection should be an additional
goal for antimicrobial stewardship programs and may
improve clinical outcome of CDI in these patients.
In addition, monitoring for cessation of other anti-
microbials when treating CDI is an important stew-
ardship measure to reduce CDI recurrence.44,80,81
2. Use contact precautions for infected patients, single-
patient room preferred (quality of evidence: III for hand
hygiene, II for gloves, III for gowns, III for single-patient
room).
a. Place patients with CDI under contact precautions to
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help reduce patient-to-patient spread of the organism.
i. Place patients in private rooms when available.
ii. Don gown and gloves upon entry to the patient’s
room.
(a) Gloves should be changed immediately if vis-
ibly soiled, after touching or handling surfaces
or materials contaminated with feces, or after
moving from a dirty to a clean intervention.
iii. Make dedicated patient care equipment readily
available (eg, stethoscopes).
(a) Use dedicated equipment whenever possible.
(b) If equipment is shared between patients, do not
bring the equipment into the patient room if
possible (eg, glucometers).
(c) Clean the piece of equipment immediately after
use. Identify who will clean and how to clean
each piece of shared equipment.
iv. Remove gown and gloves prior to exiting the
room.
v. Conduct CDC- or WHO-compliant hand hygiene
upon exiting the patient’s room.
vi. Cohorting CDI patients is acceptable when single
private rooms are not available.
(a) Place patients with stool incontinence prefer-
entially in private rooms.
(b) Do not cohort patients who are discordant with
other epidemiologically important organisms
(eg, VRE, MRSA).
(c) Remove gowns and gloves and perform hand
hygiene when moving from one patient to the
other.
b. Ensure that adequate supplies for contact precautions
are readily available.
i. Management leaders are responsible to ensure that
necessary barrier equipment supplies (eg, gowns,
gloves), dedicated equipment, and hand hygiene
products are readily available.
ii. Assign responsibility for monitoring the availabil-
ity and restocking of supplies to specific HCP.
c. Criteria for discontinuing contact precautions are as
follows:
i. The CDC currently recommends contact precau-
tions for the duration of illness when caring for
patients with CDI.82 Some experts recommend con-
tinuing contact precautions for at least 48 hours
after diarrhea resolves.
(a) After resolution of symptoms, patients with CDI
can continue to shed C. difficile in stool and
contaminate the environment.83 In addition,
these patients are at high risk for recurrent CDI
after treatment is stopped. At this time, data do
not exist to support extending isolation as a mea-
sure to decrease CDI incidence. Therefore, ex-
tending contact precautions until discharge for
all patients with CDI remains a special approach.
(b) Area of controversy. Asymptomatically colo-
nized patients who have not had CDI can shed
C. difficile spores, but the number of spores
and degree of contamination is not as great as
for patients with active CDI.72 There are cur-
rently no data to support detection or isolation
of these asymptomatic patients.
3. Ensure cleaning and disinfection of equipment and the
environment (quality of evidence: III for equipment, III
for environment).
a. C. difficile spores contaminate the environment in
which patients are housed and the equipment used
to care for them.44 This includes the following:
i. Furnishings in the room, such as overbed tables,
bedrails, furniture, sinks, floors, commodes, and
toilets.
ii. Patient care equipment that directly touches pa-
tients, such as thermometers, stethoscopes, and
blood pressure cuffs.
iii. Surfaces touched by healthcare workers and/or pa-
tients, such as doorknobs and intravenous infu-
sion pumps.
iv. C. difficile may contaminate surfaces outside patient
rooms, but the frequency of contamination and the
number of spores are much lower than are typically
present on surfaces inside CDI rooms.84,85
b. Contaminated surfaces and equipment are potential
reservoirs for transmission of C. difficile.
i. Data are conflicting as to whether inactivation of
spores is necessary to prevent C. difficile trans-
mission, especially in an endemic setting.
ii. Facilities should consider using a 1 : 10 dilution of
sodium hypochlorite (household bleach) or other
product with the EPA-approved claim for C. difficile
sporicidal activity (http://www.epa.gov/oppad001
/list_k_clostridium.pdf) to disinfect the environ-
ment in outbreak and hyperendemic settings in con-
junction with other IPC measures (see “II. Special
approaches for preventing CDI” below). The solu-
tion should have a contact time that meets the man-
ufacturers’ recommendations for C. difficile spores.
See section 4.IV.7 for a discussion of touch-free dis-
infection technologies.
c. Develop and implement protocols for disinfection of
equipment and the environment.
i. On a routine basis, assess adherence to protocols
and the adequacy of cleaning and disinfection
(http://www.cdc.gov/HAI/toolkits/Evaluating
-Environmental-Cleaning.html).
ii. Assess the adequacy of cleaning and disinfection
practices before changing to a new cleaning prod-
uct (eg, bleach). If cleaning and disinfection prac-
tices are not adequate, address this before chang-
ing products (see “II. Special approaches for
preventing CDI” below).
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iii. Ensure patient care equipment (eg, wall-mounted
sphygmomanometers) and electronic equipment
(eg, computers) that remain in the patient room
are cleaned and disinfected.
iv. Because of high turnover of environmental service
personnel, educate environmental service person-
nel on proper cleaning and disinfection technique
frequently. Ensure that education is provided in
the native language of the environmental service
personnel.
d. Dedicate noncritical patient care items, such as blood
pressure cuffs, stethoscopes, and thermometers, to a
single patient with C. difficile.
i. When this is not possible, ensure adequate cleaning
and disinfection of shared items between patient
encounters. Ensure that manufacturers’ recom-
mendations for contact time of disinfectants are
followed.
4. Implement a laboratory-based alert system to provide
immediate notification to IPC and clinical personnel
about newly diagnosed CDI patients (quality of evi-
dence: III).
a. To place patients with CDI under contact precautions
in a timely manner, it is important that an alert system
be developed between the laboratory and both IPC
and clinical personnel caring for the patient. This alert
system should immediately notify IPC and clinical
personnel when a patient is newly diagnosed with
CDI.
b. There are a variety of methods by which this infor-
mation can be transmitted, but some options include
fax alerts, phone call and pager alerts, and automated
secure electronic alerts.
i. The alert system should not rely on fax transmis-
sions alone, since there may be delays from the time
the transmission is received to the time it is seen
by an appropriate healthcare provider.
c. Alert patient care areas of positive test results im-
mediately so that these patients can be placed under
contact precautions as soon as possible. Clear pro-
tocols regarding who is responsible for reporting this
to the patient care location and who can isolate pa-
tients and remove patients from isolation should be
available.
d. When a patient has CDI, communicate the CDI status
when transferring the patient to another healthcare
facility so appropriate precautions can be imple-
mented at the accepting facility.
5. Conduct CDI surveillance and analyze and report CDI
data (quality of evidence: III).
a. At a minimum, calculate healthcare-onset, health-
care-associated CDI rates at the unit/ward and/or or-
ganizational levels (Table 1).40
b. Provide CDI data and other CDI prevention process
and outcome measures to key stakeholders, including
senior leadership, physicians, nursing staff, and other
clinicians.
c. Provide the process and outcome measures outlined
in “Section 5: Performance Measures” below to ap-
propriate hospital staff and administrators on a reg-
ular basis. The frequency with which these data are
provided will depend on the hospital’s existing re-
porting structure and the type of data collected. These
data can be added to routine quality assessment and
performance improvement reports.
6. Educate HCP, environmental service personnel, and
hospital administration about CDI (quality of evidence:
III).
a. Include risk factors, routes of transmission, local CDI
epidemiology, patient outcomes and treatment, and
prevention measures (including CDC and WHO rec-
ommendations on proper hand hygiene, contact pre-
cautions, and management of multidrug-resistant
organisms).
7. Educate patients and their families about CDI as ap-
propriate (quality of evidence: III).
a. Although often not considered part of a program to
reduce transmission of multidrug-resistant organ-
isms, proper education may help to alleviate patient
and family fears regarding being placed in isolation.86
i. Include information about anticipated questions:
general information about CDI, colonization versus
infection, the hospital’s CDI prevention program,
the components of and rationale for contact pre-
cautions, and the risk of transmission to family and
visitors while in the hospital and after discharge.
Helpful materials might include patient education
sheets in appropriate language(s), the use of patient
education channels, websites, or DVDs.
8. Measure compliance with CDC or WHO hand hygiene
and contact precaution recommendations (quality of
evidence: III).
a. Patient-to-patient transmission of C. difficile is
thought to occur primarily through transient con-
tamination of the hands of HCP with spores.
b. Glove use when caring for patients with CDI or
touching surfaces in their rooms has been shown to
be effective at preventing the transmission of C.
difficile.
c. Hand hygiene practices in compliance with CDC or
WHO guidelines may be important to C. difficile con-
trol and prevention. Evidence-based recommenda-
tions for implementation and assessment of hand hy-
giene programs in healthcare settings have been
published.77
i. Area of controversy. There are concerns regarding re-
liance on alcohol-based hand hygiene products, since
alcohol is not sporicidal. Several controlled studies
have found alcohol-based hand hygiene products to
be ineffective at removing/inactivating C. difficile
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spores from the hands of volunteers contaminated
with a known number of spores compared with hand
washing.87,88 Of note, one study did find a reduction
in spores from the palmar surface of the hand with
the alcohol-based hand hygiene product,87 and an-
other recent publication found that most hand-wash
products produced a less than 1 log10 reduction in
spores despite a 60-second hand wash (30-second
wash and 30-second rinse).89 When considering
whether to promote hand washing over alcohol-
based hand hygiene products after caring for a pa-
tient with CDI, one should also consider that con-
tamination of hands is less common when gloves are
worn for the patient encounter;59 in addition, as pre-
viously stated several clinical studies have not found
an increase in CDI with alcohol-based hand hygiene
products, but several did find reductions in MRSA
or VRE.62-68
II. Special approaches for preventing CDI
When CDI incidence remains higher than the insti-
tution’s goal, a CDI risk assessment should be performed.
Components of this risk assessment should include but
not necessarily be limited to determining the location of
new CDI cases within the affected area (ie, repeated cases
in same room or cases scattered across multiple sites), the
adequacy of contact precaution compliance, the adequacy
of hand hygiene, and the adequacy of environment and
equipment cleaning. Meetings with leadership and health-
care workers in the affected area should be conducted to
identify potential opportunities to improve the CDI pre-
vention plan. Contact the laboratory that performs the C.
difficile assay(s) to determine whether there have been any
changes in assay or assay performance.45
In addition to ensuring compliance with the basic rec-
ommendations, special approaches may be added to the
CDI prevention program. However, there are several un-
resolved issues regarding CDI prevention. This is apparent
when reviewing the rankings of each recommendation on
the basis of the quality of the data to support it. As a
result, implementation of the recommendations beyond
the basic practices to prevent CDI should be individual-
ized at each healthcare facility. One may consider a tiered
approach in which recommendations are instituted in-
dividually or in groups; additional tiers are added if CDI
rates do not improve, with implementation of basic prac-
tices as the first tier. Subsequent tiers should be prioritized
on the basis of the CDI risk assessment.
A. Approaches to minimize C. difficile transmission by HCP
1. Intensify the assessment of compliance with process
measures (quality of evidence: III).
a. Contact precautions. Gowns and gloves should be
worn by all HCP who enter the rooms of patients
under contact precautions.
b. Hand hygiene. Hand hygiene should be performed
at least on entry and exit from patient rooms.
When hand washing is performed, determine
whether proper techniques are being used.
c. If hand hygiene compliance or techniques are not
adequate, conduct interventions to improve hand
hygiene compliance and techniques.
2. During outbreaks or in settings with hyperendemic
CDI, perform hand hygiene with soap and water as
the preferred method before exiting the room of a
patient with CDI (quality of evidence: III).
a. Ensure proper hand hygiene technique when using
soap and water.
b. Be aware that hand hygiene adherence may decrease
when soap and water is the preferred method.77
i. Gloves are effective at preventing C. difficile
contamination of hands.59
ii. Hand washing may remove less than 1 log10 of
spores, even with a 60-second hand wash.89
iii. Alcohol-based hand hygiene products are su-
perior to hand washing for non-spore-forming
organisms (eg, MRSA).
iv. Reductions in CDI have not been observed with
hand washing.62-68
3. Place patients with diarrhea under contact precau-
tions while C. difficile testing is pending (quality of
evidence: III).
a. To decrease transmission, it is essential to place
symptomatic patients under contact precautions as
soon as diarrhea symptoms are recognized, as this
is the period of greatest C. difficile shedding and
contamination.83
b. If C. difficile testing is negative, the patient has a
low pretest probability of CDI, and the patient is
continent of stool, contact precautions can be
discontinued.
i. Because of concerns about the low sensitivity of
EIAs, clinical suspicion of CDI should outweigh
negative test results in patients with a high pre-
test probability of having CDI, and the patient
should remain under contact precautions.
ii. Because of its high negative predictive value, a
negative NAAT result can be helpful for remov-
ing patients with diarrhea from isolation for sus-
pected CDI.
4. Prolong the duration of contact precautions after the
patient becomes asymptomatic until hospital dis-
charge (quality of evidence: III).
B. Approaches to minimize C. difficile transmission from
the environment
1. Assess the adequacy of room cleaning (quality of evi-
dence: III).
a. If room cleaning and disinfection practices are
deemed to be inadequate, focus on reviewing and
improving cleaning and disinfection techniques.
b. Important issues to address include proper dilution
of cleaning products, adequacy of cleaning and dis-
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infection technique, cleaning high-touch surfaces,
frequency of changing rags/mop water, and moving
from clean areas to dirty areas.
i. Create a unit-specific checklist based on cleaning
protocols and perform observations to monitor
cleaning practice. Use of fluorescent markers to
monitor thoroughness of cleaning or adenosine
triphosphate (ATP) bioluminescence to measure
organic material on surfaces has been shown to
be effective in improving cleaning and disinfec-
tion performance.90,91 However, these methods
may not result in a reliable reduction in C. dif-
ficile spores from the environment.92
ii. Environmental cultures for C. difficile are dif-
ficult to perform and may require media not
commercially available, and therefore they are
not routinely recommended.93
c. Consider environmental decontamination with so-
dium hypochlorite or EPA-approved sporicidal
agent if room cleaning and disinfection is deemed
to be adequate but there is ongoing CDI trans-
mission (see below).
2. Use an EPA-approved sporicidal disinfectant or di-
luted sodium hypochlorite for environmental clean-
ing and disinfection. Implement a system to coor-
dinate with environmental services if it is determined
that sodium hypochlorite is needed for environmen-
tal disinfection (quality of evidence: III).
a. Area of controversy. Data on the ability of diluted
sodium hypochlorite or other sporicidal agents
used for environmental decontamination to con-
trol CDI have not been consistent. However, a ben-
eficial effect has been reported when bleach has
been used in outbreak or hyperendemic settings,
typically in conjunction with other enhanced CDI
control measures.94-97
b. When diluted sodium hypochlorite is instituted for
environmental decontamination, it is necessary to
coordinate activities with environmental services.
i. Clinical, IPC, and environmental service staff will
need to determine the location, type, and fre-
quency of diluted sodium hypochlorite use. For
instance:
(a) All rooms, only rooms of patients with CDI,
outside patient rooms, and so on.
(b) Daily cleaning or terminal cleaning only when
the patient is discharged or transferred? Daily
disinfection of high-touch surfaces in CDI and
MRSA rooms has been shown to reduce ac-
quisition of the pathogens on investigators’
hands after contact with surfaces and to de-
crease contamination of the hands of the pro-
viders caring for the patients.98
c. When diluted sodium hypochlorite is used, it is
important to address the following issues:
i. Avoid toxicity to patients and staff and damage
to equipment and the environment from bleach
use. Sodium hypochlorite can be corrosive and
irritating to patients, housekeepers, and other
HCP.
ii. Prior to application of diluted sodium hypo-
chlorite, surfaces must be cleaned to remove or-
ganic matter.
d. When a sporicidal method will be used only in
rooms with CDI patients, a system will need to be
created to identify these patients to environmental
service staff.
e. See section 4.IV.7 for a discussion of touch-free
disinfection technologies.
C. Approaches to reduce the risk of CDI if C. difficile is
acquired
1. Initiate an antimicrobial stewardship program (qual-
ity of evidence: II).
a. Assess appropriateness of antimicrobial prescribing
practices.
i. There are 2 primary approaches to antimicro-
bial stewardship when done specifically to pre-
vent CDI, restricting high-risk antimicrobials
and improving overall antimicrobial prescribing
practices. Of note, these approaches are not mu-
tually exclusive.
ii. Restriction of specific high-risk antimicrobials
(eg, clindamycin, cephalosporins, and fluoro-
quinolones) has been effective in outbreak
settings and should be based on local CDI ep-
idemiology.99-101 Monitoring should be con-
ducted to ensure that other antimicrobials are
not used inappropriately as a replacement for
the restricted antimicrobial. If an acceptable al-
ternative first-line antimicrobial to treat the pri-
mary non-CDI infection is not available, the
high-risk antimicrobial should be used.
iii. Improving antimicrobial prescribing practices
has been effective in outbreak and nonoutbreak
settings54,55 Research has demonstrated that a
large proportion of patients who receive anti-
microbials do not have a bacterial infection.54,55
Minimizing these unnecessary antimicrobials
reduces the number of patients at risk for CDI.
Therefore, minimizing unnecessary antimicro-
bials exposures should also reduce the number
of patients who develop CDI and contribute to
C. difficile transmission.
III. Approaches that should not be considered a routine part
of CDI prevention
1. Patients without signs or symptoms of CDI should not
be tested for C. difficile (quality of evidence: II).
a. C. difficile assays have been studied in patients with
symptoms of CDI and a high pretest probability of
having C. difficile infection. A positive C. difficile assay
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from a patient without symptoms is falsely positive
for CDI.38
i. Only stool culture for C. difficile has been confirmed
to identify patients with asymptomatic C. difficile
colonization. The sensitivity, specificity, negative pre-
dictive value, and positive predictive value of other
assays are unknown in asymptomatic patients.
b. Obtaining stool specimens requires nursing time to
collect the specimen and laboratory technician time
to perform the test and report results.
c. A positive toxin result in an asymptomatic patient
may result in the initiation of unnecessary treatment
for CDI, which may increase the patient’s risk of de-
veloping CDI in the future.102
d. Do not place patients with asymptomatic C. difficile
colonization under contact precautions.
i. Area of controversy. Routine screening for asymp-
tomatic carriage of C. difficile is not recommended.
However, patients with recent CDI are a subset of
asymptomatic carriers for whom prolongation of
contact precautions may be considered as a special
approach if basic measures are unsuccessful. The
rationale is that these patients are at high risk for
recurrence and continued shedding is common for
several weeks after successful treatment. How to
manage patients found to be colonized with C. dif-
ficile but without prior or present CDI is unclear
(eg, a patient positive by PCR but without clinically
significant diarrhea). The benefits of placing these
patients under contact precautions (decreased
transmission of C. difficile to other patients) must
be balanced with the risks (in the absence of uni-
versal screening, it will be unlikely to impact CDI
incidence) and potential for adverse events due to
contact precautions.103-106
e. Do not attempt to decolonize asymptomatic patients
since this has not been effective and may increase the
patient’s risk of developing CDI in the future.102
2. C. difficile testing should not be repeated at the end of
successful therapy in a patient recently treated for CDI
(quality of evidence: III).
a. A positive test may result in unnecessary prolongation
of contact precautions and CDI treatment.
i. In some settings, contact precautions may be ex-
tended until hospital discharge after symptom
resolution. However, there are insufficient data to
recommend extending the duration of contact pre-
cautions on the basis of whether C. difficile or its
toxins can be detected in the patient’s stool.
b. A positive test at the end of therapy does not predict
who will develop a recurrence or relapse.107
c. Repeat C. difficile testing does not provide any useful
clinical information but does require nursing time to
collect the specimen and laboratory technician time
to perform the test and report results.
d. It is not appropriate for healthcare facilities to request
repeat C. difficile testing in a patient prior to transfer
in the absence of a clinical syndrome consistent with
an undiagnosed and/or untreated case of CDI.
3. Do not routinely place patients who are on antimicro-
bials for other indications on CDI treatment to prevent
CDI (quality of evidence: III).
a. Unnecessary treatment for CDI may increase the pa-
tient’s risk of developing CDI in the future.102
IV. Unresolved issues
1. Use of gowns and gloves by family members and other
visitors.
a. The utility of requiring family members and other
visitors to wear gowns and gloves to prevent C. difficile
transmission is unknown.108 The risk that family
members and other visitors will transmit C. difficile
between patients is likely to be related to the degree
of contact the visitor has with the patient and the
patient’s environment, whether the visitor performs
hand hygiene, and the degree of interaction the visitor
has with other patients. At a minimum, family mem-
bers and other visitors should be instructed to per-
form hand hygiene whenever entering or leaving the
patient’s room. If family members do not wear gowns
and gloves, they should be educated and instructed
to use proper hand washing technique prior to leaving
the patient’s room.
2. Standing orders or nurse-driven protocols to test pa-
tients with diarrhea for C. difficile.
a. Nurses frequently identify patients with diarrhea be-
fore the treating physician does.
b. If nurses are permitted to send a stool specimen for
C. difficile testing prior to obtaining a physician order,
they should be educated on proper patient selection
for C. difficile testing (ie, clinically significant diarrhea
in a patient without other reasons for clinically sig-
nificant diarrhea).
3. Admission-based alert systems that notify IPC and clin-
ical personnel about readmitted or transferred patients
with a history of CDI.
a. This information can be integrated into a comput-
erized database used during admission and registra-
tion or a separate electronic or paper-based database.
i. If an alert system is implemented, patients with a
history of CDI should be placed under contact
precautions if they are readmitted only if they have
symptoms consistent with CDI on admission.
Asymptomatic patients with a history of CDI do
not require contact precautions.
ii. The duration that the alert should remain active is
unknown. Nearly all cases of recurrent CDI occur
within 90 days of the last episode. In light of this,
it is reasonable to eliminate the alert after 90 days
from the last episode of CDI. However, healthcare
facilities may not be aware of recurrent episodes of
CDI that are diagnosed and managed in outpatient
settings, so an arbitrary cutoff based on the last
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known episode of CDI may inadvertently remove
patients with ongoing recurrent CDI.
4. Ongoing assessment of CDI knowledge and intensified
CDI education among HCP.
a. Reeducate staff if prior CDI training occurred more
than 12 months earlier or if overall knowledge is
deemed to be inadequate.
i. Include environmental service personnel in edu-
cational efforts.
5. Restricting the use of gastric acid suppressants.
a. Whether gastric acid suppressants are a contributing
cause of CDI or a marker for patients at risk for CDI
is not clear. There are no data suggesting restricting
gastric acid suppressants is associated with reductions
in CDI.
6. Prescribing probiotics as primary prophylaxis.
a. Recent meta-analyses indicated that probiotics may be
effective as primary prophylaxis against CDI.109,110 A
concern with these meta-analyses is that the studies
with the greatest weight had extremely high incidences
of CDI in the placebo groups (7%, 24%, and 40%).
The incidence of CDI in high-risk patients without
contraindications to probiotics is typically less than or
equal to 3%.111,112 The high incidence of CDI in the
placebo group has the potential to bias their findings
to favor the probiotics. For example, a recent large
randomized controlled trial of probiotic versus placebo
with a more typical CDI incidence in the placebo arm
(1.2%) failed to demonstrate a reduction in CDI with
the use of a probiotic.113 In addition, many hospitalized
patients have relative contraindications to probiotics
(eg, central venous catheter, immunocompromised)
that place them at increased risk of infection due to
the probiotic strain(s).114
7. No-touch disinfection technologies.
a. Several no-touch disinfection products are commer-
cially available. In general, these products use ultra-
violet light or hydrogen peroxide vapor to disinfect
the environment.73,92,115 These devices kill C. difficile
spores, and several studies have found them to be
effective at reducing cultivatable C. difficile from pa-
tient rooms.73,92,115 Although sporicidal activity can be
achieved without requiring a person to wipe down a
surface, the use of these devices does not preclude
the need to manually clean soiled surfaces.73,92 Data
are currently too limited to draw any conclusions as
to whether or when these devices should be a com-
ponent of a CDI prevention program. In addition,
excellent results can be achieved with manual cleaning
with a sporicidal disinfectant.92
section 5: performance measures
I. Internal reporting
These performance measures are intended to support
internal hospital quality improvement efforts and do not
necessarily address external reporting needs. The process
and outcome measures suggested here are derived from
published guidelines, other relevant literature, and the
opinions of the authors. Report process and outcome mea-
sures to senior hospital leadership, nursing leadership, and
clinicians who care for patients at risk for CDI.
A. Process measures
1. Compliance with hand hygiene guidelines.
a. Preferred measure for hand hygiene compliance.
i. Numerator: number of observed proper hand
hygiene episodes performed by HCP.
ii. Denominator: total number of observed op-
portunities for hand hygiene.
iii. Multiply by 100 so that the measure is expressed
as a percentage.
b. If hand hygiene with soap and water is the pre-
ferred method of hand hygiene when caring for
patients with CDI, also assess proper hand washing
techniques.
i. Numerator: number of proper hand washing
episodes with proper technique.
ii. Denominator: total number of hand washing
episodes observed.
iii. Multiply by 100 so that the measure is expressed
as a percentage.
2. Compliance with contact precautions.
a. Preferred measure of contact precautions
compliance.
i. Numerator: number of observed patient care
episodes in which contact precautions are ap-
propriately implemented.
ii. Denominator: number of observed patient care
episodes in which contact precautions are
indicated.
iii. Multiply by 100 so that the measure is expressed
as a percentage.
3. Compliance with environmental cleaning and
disinfection.
a. One specific measure of compliance for use in all
hospitals cannot be recommended. However, many
hospitals use checklists, environmental rounds,
fluorescent markers, and/or ATP bioluminescence
to assess the cleaning and disinfection process and
the cleanliness of equipment and the environment
(see above).
B. Outcome measures
Perform ongoing measurement of the incidence den-
sity of CDI to permit longitudinal assessment of the
processes of care.
1. CDI rates should be calculated according to the re-
cently published recommendations and as described
above.
a. See Table 1 for case definitions.
i. Numerator: number of CDI cases in the pop-
ulation being monitored (specific cases in-
cluded in the numerator depends on the defi-
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table 3. Fundamental Elements of Accountability for Healthcare-Associated Infection Prevention
Senior management is responsible for ensuring that the healthcare system supports an infection prevention and control (IPC) pro-
gram that effectively prevents healthcare-associated infections (HAIs) and the transmission of epidemiologically important
pathogens
Senior management is accountable for ensuring that an adequate number of trained personnel are assigned to the IPC program and
adequate staffing of other departments that play a key role in HAI prevention (eg, environmental services)
Senior management is accountable for ensuring that healthcare personnel, including licensed and nonlicensed personnel, are ade-
quately trained and competent to perform their job responsibilities
Direct healthcare providers (such as physicians, nurses, aides, and therapists) and ancillary personnel (such as environmental service
and equipment processing personnel) are responsible for ensuring that appropriate IPC practices are used at all times (including
hand hygiene, standard and isolation precautions, and cleaning and disinfection of equipment and the environment)
Senior and unit leaders are responsible for holding personnel accountable for their actions
IPC leadership is responsible for ensuring that an active program to identify HAIs is implemented, that HAI data are analyzed and
regularly provided to those who can use the information to improve the quality of care (eg, unit staff, clinicians, and hospital
administrators), and that evidence-based practices are incorporated into the program
Senior and unit leaders are accountable for ensuring that appropriate training and educational programs to prevent HAIs are devel-
oped and provided to personnel, patients, and families
Personnel from the IPC program, the laboratory, and information technology departments are responsible for ensuring that systems
are in place to support the surveillance program
nition used; see Table 1).
ii. Denominator: total number of patient-days in
the population being monitored.
iii. Multiply by 10,000 so that the measure is ex-
pressed as the number of cases per 10,000
patient-days (note: to convert the rate per
10,000 patient-days to 1,000 patient-days, di-
vide the rate by 10; conversely, to convert a rate
from 1,000 patient-days to 10,000 patient-days,
multiply the rate by 10).
II. External reporting
There are many challenges in providing useful infor-
mation to consumers and other stakeholders while pre-
venting unintended adverse consequences of public
reporting of HAIs.116 Recommendations for public re-
porting of HAIs have been provided by the Hospital
Infection Control Practices Advisory Committee, the
Healthcare-Associated Infection Working Group of the
Joint Public Policy Committee, and the National Quality
Forum.116,117
A. State and federal requirements
1. The CMS began requiring acute care hospitals par-
ticipating in their Inpatient Prospective Payment Sys-
tem to report laboratory-identified CDI using NHSN
in January 2013.
2. For information on local requirements, check with
your state or local health department.
B. External quality initiatives
1. Hospitals that participate in external quality initia-
tives must collect and report the data if required by
the initiative.
section 6: examples of
implementation strategies
Accountability is an essential principle for preventing HAIs.
It provides the necessary translational link between science
and implementation. Without clear accountability, scientifi-
cally based implementation strategies will be used in an in-
consistent and fragmented way, decreasing their effectiveness
in preventing HAIs. Accountability begins with the chief ex-
ecutive officer and other senior leaders who provide the im-
perative for HAI prevention, thereby making HAI prevention
an organizational priority. Senior leadership is accountable
for providing adequate resources needed for effective imple-
mentation of an HAI prevention program. These resources
include necessary personnel (clinical and nonclinical), edu-
cation, and equipment (Table 3).
Successful implementation strategies used as part of col-
laboratives and working groups include engage, educate, ex-
ecute, and evaluate.96,118 Strategies that have been shown to
be effective in addressing CDI within healthcare settings are
provided in this section.
I. Engage
A. Multidisciplinary involvement
1. To address the complexities involved in the imple-
mentation of prevention strategies for CDI, broad-
scope involvement of hospital personnel should be
an integral part of the process. This approach serves
to engage key stakeholders in the prevention and care
stages of the infection.
2. Identification and engagement of a multidisciplinary
team should be an initial step in implementation of
a CDI prevention plan. The team should involve rep-
resentation from senior leadership, unit-level lead-
ership, individual healthcare providers, laboratory
personnel, pharmacy, environmental services, mate-
rials management, and information technology. Goals
should be established and accountability embedded
in the process. Recent successes have been demon-
strated through development of a multidisciplinary
and specific C. difficile infection control plan based
on a risk assessment.96
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II. Educate
A. Educate personnel
1. Provide education to HCP, environmental services
personnel, executive level leadership, and others, in-
cluding at least the following: risk factors for CDI,
transmission, local epidemiology, patient outcomes,
treatment, hand hygiene, contact precautions, man-
agement of multidrug-resistant organisms, and in-
dividual job responsibilities.77,108 Provide information
in the native language of the personnel whenever
possible.
2. Identify and implement methods for education and
training of personnel that allow immersive experi-
ences that enhance critical thinking and decision-
making skills, including simulation experiences.119
B. Educate patients and their families about CDI
1. Provide education to patients and their families re-
garding CDI (http://www.cdc.gov/hai/organisms
/cdiff/Cdiff-patient.html). Education should in-
clude at least the following: general information
about CDI (including risk for recurrent CDI), col-
onization versus infection, elements in the facility
CDI prevention program, components of and ratio-
nale for contact precautions, and risks of transmis-
sion to family and visitors while in the hospital and
after discharge.
2. Provide education and assist patients with perfor-
mance of hand hygiene as an approach to preventing
acquisition of pathogens.120
III. Execute
A. Initiate a CDI prevention program
1. Perform a CDI risk assessment as a basis for a com-
prehensive and multidisciplinary intervention.96
a. Define local CDI epidemiology.
i. Identify high-risk wards and wards with a high
incidence of hospital-onset CDI.
ii. Determine whether hospital-onset CDI cases are
sporadic or occur repeatedly in the same
room(s).121
(a) If sporadic, suggests patient-to-patient trans-
mission from healthcare workers or traveling
fomites.
(b) If repeated in same room, suggests trans-
mission from contaminated environment.
2. Pilot-test the intervention in one patient care location
to assess efficacy.
a. Initiate the prevention program where there is a
high concentration of patients at risk for CDI, such
as an intensive care unit or an oncology ward.
b. Start in one patient care location.
i. Identify opportunities to improve the system
for identifying patients with CDI.
ii. Identify opportunities to improve the process
for placing patients with CDI in contact pre-
caution rooms and to minimize problems for
family members, visitors, and HCP.
iii. Identify opportunities to optimize hand hy-
giene, contact precautions, and environmental
cleaning compliance.
c. Obtain support of the hospital administration and
local physician and nursing leadership prior to
starting the program.
d. Standardize care processes and practices using
bundles, checklists, protocols, and guidelines.94,96
Empower staff to report process defects to appro-
priate personnel as a means of facilitating rapid
intervention and identification of barriers. Assign
accountability for adherence to specific depart-
ments or functions.96
e. Create redundancy in the system by incorporating
use of visual cues as reminders and assistance to
recall. For example, have indicators that the patient
is under contact precautions in the electronic med-
ical records, paper medical records, and signage on
the door to the patient room.
3. Replicate the CDI IPC program in other patient care




1. Use process measures (did you successfully implement
your intervention?) and outcome measures (how well
did the intervention achieve the desired outcome?) to
determine whether the intervention is effective.
2. Measure both process and outcomes on a regular
basis.
B. Feedback to staff
1. Provide monitoring data in various formats so it can
be posted and broadly disseminated. Incorporate
monitoring data into unit-based and department-
based measurements so trending over time can be
evaluated.94,96
2. Provide feedback to all levels of personnel regarding
process and outcomes. Provide feedback via com-
mittee reports as well as facility newsletters.
3. Individualize feedback so respective patient care areas
and individual departments can use data for com-
parative and goal-setting purposes.
4. Use feedback to determine specific interventions or
improvements for targeted focus.118
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